Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Silvia Minozzi, Stefanos Bonovas, Theodore Lytras, Valentina Pecoraro, Marien González-Lorenzo, Anan Judina Bastiampillai, Eugenia Maria Gabrielli, Andrea Carlo Lonati, Lorenzo Moja, Michela Cinquini, Valentina Marino, Andrea Matucci, Giuseppe Maria Milano, Giuliano Tocci, Raffaele Scarpa, Delia Goletti & Fabrizio Cantini. (2016) Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety 15:sup1, pages 11-34.
Read now
Read now
L. E. Kristensen, R. Christensen, H. Bliddal, P. Geborek, B. Danneskiold‐Samsøe & T. Saxne. (2007) The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scandinavian Journal of Rheumatology 36:6, pages 411-417.
Read now
Read now
Bart JF van den Bemt, Frank HJ van den Hoogen, Ferdinand C Breedveld,Hille van der Tempel & Rob Janknegt. (2006) InforMatrix®: treatment of rheumatoid arthritis using biologicals. Expert Opinion on Pharmacotherapy 7:13, pages 1769-1789.
Read now
Read now
Articles from other publishers (31)
Gerd R. Burmester, Kenneth B. Gordon, James T. Rosenbaum, Dilek Arikan, Winnie L. Lau, Peigang Li, Freddy Faccin & Remo Panaccione. (2019) Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Advances in Therapy 37:1, pages 364-380.
Crossref
Crossref
Jasvinder A Singh, Alomgir Hossain, Amy S Mudano, Elizabeth Tanjong Ghogomu, Maria E Suarez-Almazor, Rachelle Buchbinder, Lara J Maxwell, Peter Tugwell & George A Wells. (2017) Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Lara J Maxwell, Rachelle Buchbinder, Maria Angeles Lopez-Olivo, Maria E Suarez-Almazor, Peter Tugwell & George A Wells. (2017) Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2017:3.
Crossref
Crossref
Calen A. Steiner, Emily P. Whitfield, Jeremy Adler & Peter D. R. Higgins. 2017. Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease
401
416
.
Sophie De Mits, Jan Lenaerts, Bert Vander Cruyssen, Herman Mielants, René Westhovens, Patrick Durez & Dirk Elewaut. (2016) A Nationwide Survey on Patient’s versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study. PLOS ONE 11:11, pages e0166607.
Crossref
Crossref
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Peter Tugwell & George A Wells. (2016) Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Cochrane Database of Systematic Reviews 2016:11.
Crossref
Crossref
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Ahmed Kotb, Robin Christensen, Amy S Mudano, Lara J Maxwell, Nipam P Shah, Peter Tugwell & George A Wells. (2016) Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2016:5.
Crossref
Crossref
Jaime C. Branco, Anabela Barcelos, Filipe Pombo de Araújo, Graça Sequeira, Inês Cunha, José Vaz Patto, Margarida Oliveira, Margarida Pratas Mateus, Maura Couto, Patrícia Nero, Patrícia Pinto, Paulo Monteiro, Walter Castelão, Jorge Félix, Diana Ferreira, João Almeida & Maria João Silva. (2016) Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study. Advances in Therapy 33:1, pages 46-57.
Crossref
Crossref
Tzeyu L. Michaud, Young Hee Rho, Tatyana Shamliyan, Karen M. Kuntz & Hyon K. Choi. (2014) The Comparative Safety of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-analysis Update of 44 Trials. The American Journal of Medicine 127:12, pages 1208-1232.
Crossref
Crossref
Jean H Tayar, Maria A Lopez-Olivo & Maria E Suarez-Almazor. (2013) Adalimumab: 8 years of experience in rheumatoid arthritis. International Journal of Clinical Rheumatology 8:2, pages 165-184.
Crossref
Crossref
Wojciech Blonski, Faten Aberra & Gary R. Lichtenstein. 2013. Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease
357
383
.
Aatke van der Maas, Bart JF van den Bemt, Gertjan Wolbink, Frank HJ van den Hoogen, Piet LCM van Riel & Alfons A den Broeder. (2012) Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. BMC Musculoskeletal Disorders 13:1.
Crossref
Crossref
Bart JF van den Bemt, Alfons A den Broeder, GJ Wolbink, Yechiel A Hekster, Piet LCM van Riel, Bart Benraad & Frank HJ van den Hoogen. (2011) Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study. BMC Musculoskeletal Disorders 12:1.
Crossref
Crossref
INGRID M. VISMAN, GEERTJE M. BARTELDS, WOUTER OUWERKERK, ANITA C.J. RAVELLI, LINDA M. PEELEN, BEN A.C. DIJKMANS, MAARTEN BOERS & MIKE T. NURMOHAMED. (2011) Effect of the Application of Trial Inclusion Criteria on the Efficacy of Adalimumab Therapy in a Rheumatoid Arthritis Cohort. The Journal of Rheumatology 38:9, pages 1884-1890.
Crossref
Crossref
EDWARD C. KEYSTONE, ARTHUR KAVANAUGH, MICHAEL E. WEINBLATT, KAUSHIK PATRA & AILEEN L. PANGAN. (2011) Clinical Consequences of Delayed Addition of Adalimumab to Methotrexate Therapy Over 5 Years in Patients with Rheumatoid Arthritis. The Journal of Rheumatology 38:5, pages 855-862.
Crossref
Crossref
Jasvinder A Singh, George A Wells, Robin Christensen, Elizabeth Tanjong Ghogomu, Lara J Maxwell, John K MacDonald, Graziella Filippini, Nicole Skoetz, Damian K Francis, Luciane C Lopes, Gordon H Guyatt, Jochen Schmitt, Loredana La Mantia, Tobias Weberschock, Juliana F Roos, Hendrik Siebert, Sarah Hershan, Chris Cameron, Michael PT Lunn, Peter Tugwell & Rachelle Buchbinder. (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2016:4.
Crossref
Crossref
Alberto Alonso-Ruiz, Jose Ignacio Pijoan, Eukene Ansuategui, Arantxa Urkaregi, Marcelo Calabozo & Antonio Quintana. (2008) Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskeletal Disorders 9:1.
Crossref
Crossref
Maria A. Lopez-Olivo, Michael A. Kallen, Zulma Ortiz, Becky Skidmore & Maria E. Suarez-Almazor. (2008) Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: A systematic review. Arthritis & Rheumatism 59:11, pages 1625-1638.
Crossref
Crossref
Sharon E. Jacob, Robyn S. Weisman & Francisco A. Kerdel. (2008) Pyoderma gangrenosum - rebel without a cure?. International Journal of Dermatology 47:2, pages 192-194.
Crossref
Crossref
Jeanne Tung & William J. Sandborn. 2008. Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease
403
427
.
Margaret Wisłowska & Danuta Jakubicz. (2007) Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-α blocker plus methotrexate versus methotrexate or leflunomide alone. Rheumatology International 27:7, pages 641-647.
Crossref
Crossref
Ho-Youn KIM, Soo-Kon LEE, Yeong Wook SONG, Dae-Hyun YOO, Eun-Mi KOH, Bin YOO & Allison LUO. (2007) A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR Journal of Rheumatology 10:1, pages 9-16.
Crossref
Crossref
Jean–Frédéric Colombel, William J. Sandborn, Paul Rutgeerts, Robert Enns, Stephen B. Hanauer, Remo Panaccione, Stefan Schreiber, Dan Byczkowski, Ju Li, Jeffrey D. Kent & Paul F. Pollack. (2007) Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial. Gastroenterology 132:1, pages 52-65.
Crossref
Crossref
Bruno Fautrel, Arnaud Constantin, Jacques Morel, Olivier Vittecoq, Alain Cantagrel, Bernard Combe, Maxime Dougados, Xavier Le Loët, Xavier Mariette, Thao Pham, Xavier Puéchal, Jean Sibilia, Martin Soubrier & Philippe Ravaud. (2006) Recommandations de la Société française de rhumatologie pour l'utilisation des agents anti-TNFα chez les personnes souffrant de polyarthrite rhumatoïde. Revue du Rhumatisme 73:7, pages 726-735.
Crossref
Crossref
Bruno Fautrel, Arnaud Constantin, Jacques Morel, Olivier Vittecoq, Alain Cantagrel, Bernard Combe, Maxime Dougados, Xavier Le Loët, Xavier Mariette, Thao Pham, Xavier Puéchal, Jean Sibilia, Martin Soubrier & Philippe Ravaud. (2006) Recommendations of the French Society for Rheumatology. TNFα antagonist therapy in rheumatoid arthritis. Joint Bone Spine 73:4, pages 433-441.
Crossref
Crossref
Stephen B. Hanauer, William J. Sandborn, Paul Rutgeerts, Richard N. Fedorak, Milan Lukas, Donald MacIntosh, Remo Panaccione, Douglas Wolf & Paul Pollack. (2006) Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial. Gastroenterology 130:2, pages 323-333.
Crossref
Crossref
L. Bernal Rivera, M.D. Guerrero Aznar, A. Monzón Moreno, M. Beltrán García, B. Hernández Cruz & M.A. Colmenero. (2006) Efectividad y seguridad de adalimumab y etanercept en artritis reumatoide en un hospital de tercer nivel. Farmacia Hospitalaria 30:4, pages 223-229.
Crossref
Crossref
David J. Rychly & Joseph T. DiPiro. (2012) Infections Associated with Tumor Necrosis Factor‐α Antagonists. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 25:9, pages 1181-1192.
Crossref
Crossref
Federico Navarro-Sarabia, Rafael Ariza-Ariza, Blanca Hernandez-Cruz & Isidro Villanueva. (2005) Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Susan J Lee & Arthur Kavanaugh. (2005) Adalimumab for the treatment of rheumatoid arthritis. Therapy 2:1, pages 13-21.
Crossref
Crossref
Arthur Kavanaugh & Susan J Lee. (2005) Adalimumab for the treatment of rheumatoid arthritis. Therapy 2:1, pages 13-21.
Crossref
Crossref